To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.

Inclusion Criteria:

1. Female, 18-75 years old;
2. Expected survival ≥ 12 weeks;
3. Subjects with ECOG score of physical state 0~1;
4. Histologically confirmed recurrent or metastatic advanced breast cancer;

Exclusion Criteria:

1. Those who have had a severe allergic reaction to any drug or its components in thisstudy in the past;
2. Present with primary central nervous system (CNS) malignancies; Subjects with CNSmetastasis who have failed local treatment (except asymptomatic BMS, or symptomaticBMS with complete remission of symptoms ≥ 2 weeks after treatment for BMS);
3. Has any disease or syndrome that requires or is likely to require systemic steroidtherapy during the study period;
4. Gastrointestinal disorders or gastrointestinal diseases will significantly affect theabsorption of test drugs (such as ulcerative disease, uncontrolled vomiting, diarrhea,malabsorption syndrome, biliary drainage status, etc.), or subjects cannot take drugsorally: